PF-Atlas › Clinical Trials › NCT01347190
Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor in Subjects With Cystic Fibrosis
CR002 Liquid API · Phase 1
Registry ID
NCT01347190
Phase
Phase 1
Status
Completed
Drug / intervention
CR002 Liquid API
Sponsor
CSL Behring
Start
2011-04
Enrollment
25
Locations
11
About this trial
Study to assess safety and tolerability of a single dose of study-drug administered to Cystic Fibrosis (CF) patients.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT01347190 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.